Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Gastrointestinal 1

Conditions

Chemotherapy-induced Peripheral Neuropathy 1

Interventions

naloxegol 7alvimopan 6Radiotherapy 5angiotensin I (1-7) 4Cisplatin 4tegaserod 3Injections 3RRx-001 2Fibroblast Growth Factor 7 2tempol 1prucalopride 1oxycodone naloxone combination 1naldemedine 1methylnaltrexone 1linaclotide 1licogliflozin 1hydrated silica gel-based toothpaste 1golotimod 1brilacidin 1apraglutide 1amlexanox 1aluminum hydroxide, magnesium hydroxide, drug combination 1Xylitol 1Water 1Therapeutics 1Testosterone Propionate 1Robotic Surgical Procedures 1Radiotherapy, Intensity-Modulated 1Phenylephrine 1Oxycodone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × ART123 × Other × Clear all
NCT05251727 2024-08-19

Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients

Veloxis Pharmaceuticals

Phase 1 Terminated
77 enrolled
Other

Chemotherapy-induced Peripheral Neuropathy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡